Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

Anna Kajaste-Rudnitski, Laura Galli, Silvia Nozza, Giuseppe Tambussi, Andrea Di Pietro, Gabriele Pellicciotta, Alessandro Monti, Paolo Mascagni, Matteo Moro, Elisa Vicenzi

Research output: Contribution to journalArticle

Abstract

Objective: To determine the immunogenicity of the monovalent vaccine against 2009 pandemic influenza A/H1N1 in HIV-1-infected individuals. Design: A total of 192 participants, including 44 HIV-1-positive individuals and 148 HIV-1-negative healthy controls were enrolled to receive a single dose of MF59-adjuvanted 2009 A/H1N1v vaccine formulated to contain 7.5 μg of haemagglutin antigen. Methods: Standard haemagglutination inhibition (HAI) assay was performed to evaluate seroconversion and seroprotecsion rates against the pandemic virus in serum samples collected at baseline (T0) and 3-5-week postvaccination (T28). Seroconversion to vaccination was defined by either prevaccination HAI titer less than 1: 10 with a postvaccination titer higher than 1: 40, or a prevaccination titer higher than 1: 10 and increase of at least four-fold or more after vaccination. Seroprotection was defined by HAI titers higher than 1: 40. Results: The vaccine induced specific antibody titers in HIV-1-positive individuals similar to those of HIV-1-negative controls [215.3, 95% confidence interval (CI) 150.4-308.1 vs. 275.9, 95% CI 232.6-327.3] with postvaccination seroprotection rates higher than 97%. In contrast, the seroconversion rate was lower in the HIV-1-positive individuals as compared with the HIV-1-negative controls (36.4 vs. 79.0%, P <0.0001), likely as a consequence of their high HAI baseline titers. Multivariable logistic regression analysis showed that seroconversion was less likely in HIV-1-positive individuals [odds ratio (OR) = 0.237, 95% CI 0.104-0.539, P = 0.0006) and with increasing age (OR = 0.805, 95% CI 0.684-0.947, P = 0.009). Conclusions: A single dose of MF59-adjuvanted 2009 influenza H1N1 vaccine induced an immune response against pandemic H1N1 virus in HIV-1-positive individuals reaching titers similar to those of HIV-1-negative individuals. The seroconversion rate was negatively associated with HIV infection and increasing age.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalAIDS (London, England)
Volume25
Issue number2
DOIs
Publication statusPublished - Jan 14 2011

Fingerprint

Influenza Vaccines
Pandemics
Antibody Formation
HIV-1
Hemagglutination
Confidence Intervals
Vaccination
Vaccines
Odds Ratio
MF59 oil emulsion
H1N1 Subtype Influenza A Virus
Human Influenza
HIV Infections
Logistic Models
Regression Analysis
Seroconversion
Viruses
Antigens
Antibodies

Keywords

  • HIV-positive and HIV-negative individuals
  • MF-59 adjuvant
  • pandemic influenza vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. / Kajaste-Rudnitski, Anna; Galli, Laura; Nozza, Silvia; Tambussi, Giuseppe; Di Pietro, Andrea; Pellicciotta, Gabriele; Monti, Alessandro; Mascagni, Paolo; Moro, Matteo; Vicenzi, Elisa.

In: AIDS (London, England), Vol. 25, No. 2, 14.01.2011, p. 177-183.

Research output: Contribution to journalArticle

@article{826074858cb842c9992ee33c5cc34b59,
title = "Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals",
abstract = "Objective: To determine the immunogenicity of the monovalent vaccine against 2009 pandemic influenza A/H1N1 in HIV-1-infected individuals. Design: A total of 192 participants, including 44 HIV-1-positive individuals and 148 HIV-1-negative healthy controls were enrolled to receive a single dose of MF59-adjuvanted 2009 A/H1N1v vaccine formulated to contain 7.5 μg of haemagglutin antigen. Methods: Standard haemagglutination inhibition (HAI) assay was performed to evaluate seroconversion and seroprotecsion rates against the pandemic virus in serum samples collected at baseline (T0) and 3-5-week postvaccination (T28). Seroconversion to vaccination was defined by either prevaccination HAI titer less than 1: 10 with a postvaccination titer higher than 1: 40, or a prevaccination titer higher than 1: 10 and increase of at least four-fold or more after vaccination. Seroprotection was defined by HAI titers higher than 1: 40. Results: The vaccine induced specific antibody titers in HIV-1-positive individuals similar to those of HIV-1-negative controls [215.3, 95{\%} confidence interval (CI) 150.4-308.1 vs. 275.9, 95{\%} CI 232.6-327.3] with postvaccination seroprotection rates higher than 97{\%}. In contrast, the seroconversion rate was lower in the HIV-1-positive individuals as compared with the HIV-1-negative controls (36.4 vs. 79.0{\%}, P <0.0001), likely as a consequence of their high HAI baseline titers. Multivariable logistic regression analysis showed that seroconversion was less likely in HIV-1-positive individuals [odds ratio (OR) = 0.237, 95{\%} CI 0.104-0.539, P = 0.0006) and with increasing age (OR = 0.805, 95{\%} CI 0.684-0.947, P = 0.009). Conclusions: A single dose of MF59-adjuvanted 2009 influenza H1N1 vaccine induced an immune response against pandemic H1N1 virus in HIV-1-positive individuals reaching titers similar to those of HIV-1-negative individuals. The seroconversion rate was negatively associated with HIV infection and increasing age.",
keywords = "HIV-positive and HIV-negative individuals, MF-59 adjuvant, pandemic influenza vaccine",
author = "Anna Kajaste-Rudnitski and Laura Galli and Silvia Nozza and Giuseppe Tambussi and {Di Pietro}, Andrea and Gabriele Pellicciotta and Alessandro Monti and Paolo Mascagni and Matteo Moro and Elisa Vicenzi",
year = "2011",
month = "1",
day = "14",
doi = "10.1097/QAD.0b013e328341afa8",
language = "English",
volume = "25",
pages = "177--183",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

AU - Kajaste-Rudnitski, Anna

AU - Galli, Laura

AU - Nozza, Silvia

AU - Tambussi, Giuseppe

AU - Di Pietro, Andrea

AU - Pellicciotta, Gabriele

AU - Monti, Alessandro

AU - Mascagni, Paolo

AU - Moro, Matteo

AU - Vicenzi, Elisa

PY - 2011/1/14

Y1 - 2011/1/14

N2 - Objective: To determine the immunogenicity of the monovalent vaccine against 2009 pandemic influenza A/H1N1 in HIV-1-infected individuals. Design: A total of 192 participants, including 44 HIV-1-positive individuals and 148 HIV-1-negative healthy controls were enrolled to receive a single dose of MF59-adjuvanted 2009 A/H1N1v vaccine formulated to contain 7.5 μg of haemagglutin antigen. Methods: Standard haemagglutination inhibition (HAI) assay was performed to evaluate seroconversion and seroprotecsion rates against the pandemic virus in serum samples collected at baseline (T0) and 3-5-week postvaccination (T28). Seroconversion to vaccination was defined by either prevaccination HAI titer less than 1: 10 with a postvaccination titer higher than 1: 40, or a prevaccination titer higher than 1: 10 and increase of at least four-fold or more after vaccination. Seroprotection was defined by HAI titers higher than 1: 40. Results: The vaccine induced specific antibody titers in HIV-1-positive individuals similar to those of HIV-1-negative controls [215.3, 95% confidence interval (CI) 150.4-308.1 vs. 275.9, 95% CI 232.6-327.3] with postvaccination seroprotection rates higher than 97%. In contrast, the seroconversion rate was lower in the HIV-1-positive individuals as compared with the HIV-1-negative controls (36.4 vs. 79.0%, P <0.0001), likely as a consequence of their high HAI baseline titers. Multivariable logistic regression analysis showed that seroconversion was less likely in HIV-1-positive individuals [odds ratio (OR) = 0.237, 95% CI 0.104-0.539, P = 0.0006) and with increasing age (OR = 0.805, 95% CI 0.684-0.947, P = 0.009). Conclusions: A single dose of MF59-adjuvanted 2009 influenza H1N1 vaccine induced an immune response against pandemic H1N1 virus in HIV-1-positive individuals reaching titers similar to those of HIV-1-negative individuals. The seroconversion rate was negatively associated with HIV infection and increasing age.

AB - Objective: To determine the immunogenicity of the monovalent vaccine against 2009 pandemic influenza A/H1N1 in HIV-1-infected individuals. Design: A total of 192 participants, including 44 HIV-1-positive individuals and 148 HIV-1-negative healthy controls were enrolled to receive a single dose of MF59-adjuvanted 2009 A/H1N1v vaccine formulated to contain 7.5 μg of haemagglutin antigen. Methods: Standard haemagglutination inhibition (HAI) assay was performed to evaluate seroconversion and seroprotecsion rates against the pandemic virus in serum samples collected at baseline (T0) and 3-5-week postvaccination (T28). Seroconversion to vaccination was defined by either prevaccination HAI titer less than 1: 10 with a postvaccination titer higher than 1: 40, or a prevaccination titer higher than 1: 10 and increase of at least four-fold or more after vaccination. Seroprotection was defined by HAI titers higher than 1: 40. Results: The vaccine induced specific antibody titers in HIV-1-positive individuals similar to those of HIV-1-negative controls [215.3, 95% confidence interval (CI) 150.4-308.1 vs. 275.9, 95% CI 232.6-327.3] with postvaccination seroprotection rates higher than 97%. In contrast, the seroconversion rate was lower in the HIV-1-positive individuals as compared with the HIV-1-negative controls (36.4 vs. 79.0%, P <0.0001), likely as a consequence of their high HAI baseline titers. Multivariable logistic regression analysis showed that seroconversion was less likely in HIV-1-positive individuals [odds ratio (OR) = 0.237, 95% CI 0.104-0.539, P = 0.0006) and with increasing age (OR = 0.805, 95% CI 0.684-0.947, P = 0.009). Conclusions: A single dose of MF59-adjuvanted 2009 influenza H1N1 vaccine induced an immune response against pandemic H1N1 virus in HIV-1-positive individuals reaching titers similar to those of HIV-1-negative individuals. The seroconversion rate was negatively associated with HIV infection and increasing age.

KW - HIV-positive and HIV-negative individuals

KW - MF-59 adjuvant

KW - pandemic influenza vaccine

UR - http://www.scopus.com/inward/record.url?scp=78650879808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650879808&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328341afa8

DO - 10.1097/QAD.0b013e328341afa8

M3 - Article

C2 - 21150561

AN - SCOPUS:78650879808

VL - 25

SP - 177

EP - 183

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -